8-K: Pulse Biosciences Q2 Loss Widens Amid Clinical Advances

Pulse Biosciences reported increased losses and expenses in Q2 2025, despite significant clinical progress in its nsPFA technology programs.

Summary

• Total GAAP costs and expenses for the three months ended June 30, 2025, were $20.3 million, an increase of $8.5 million from $11.7 million in the prior year period.
• Non-GAAP costs and expenses for the three months ended June 30, 2025, were $14.8 million, an increase of $5.4 million from $9.4 million in the prior year period.
• GAAP net loss for the second quarter of 2025 was ($19.2) million, compared to ($11.4) million for the same period in 2024.
• Non-GAAP net loss for the second quarter of 2025 was ($13.7) million, compared to ($9.0) million for the same period in 2024.
• Cash and cash equivalents totaled $106.3 million as of June 30, 2025, down from $119.3 million as of March 31, 2025, but up from $26.2 million as of June 30, 2024.
• Cash used in operating activities in Q2 2025 was $12.8 million, compared to $8.4 million in Q2 2024 and $13.5 million in Q1 2025.
• Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation, treating over 140 Benign Thyroid Nodule patients.
• Submitted FDA IDE applications, including pivotal study protocols, for both the nsPFA Cardiac Surgery System and the nsPFA 360 catheter for AF ablation.
• Treated 40 patients in Europe with the nsPFA Cardiac Surgery System, generating positive clinical outcomes.
• Treated over 140 total patients with the nsPFA 360 catheter in Europe, observing improved procedure times.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While clinical progress and milestones are positive, the significant increase in GAAP and Non-GAAP net losses, coupled with a higher cash burn rate, indicates deteriorating financial performance. The cash balance, while substantial, is being depleted at an accelerated pace, raising concerns about future liquidity without a clear path to revenue generation.

Positives

• Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation, treating over 140 benign thyroid nodule patients.
• Identified five sites for a post-market study of benign thyroid disease treatment, with enrollment planned for Q3 upon IRB approvals.
• Submitted FDA IDE applications for both the cardiac surgical clamp and nsPFA 360 catheter, including pivotal study protocols, remaining on track to commence pivotal studies in the next few months.
• Generated positive clinical outcomes from follow-up remapping procedures in 40 patients treated with the nsPFA Cardiac Surgery System in Europe.
• Observed improved procedure times with the nsPFA 360 catheter since April, treating over 140 total patients in Europe.

Negatives

• Total GAAP costs and expenses increased by $8.5 million to $20.3 million in Q2 2025 compared to Q2 2024, primarily due to administrative expenses for organizational expansion and non-cash stock-based compensation.
• Non-GAAP costs and expenses increased by $5.4 million to $14.8 million in Q2 2025 compared to Q2 2024.
• GAAP net loss widened to ($19.2) million in Q2 2025 from ($11.4) million in Q2 2024.
• Non-GAAP net loss widened to ($13.7) million in Q2 2025 from ($9.0) million in Q2 2024.
• Cash used in operating activities increased to $12.8 million in Q2 2025 from $8.4 million in Q2 2024.
• Cash and cash equivalents decreased by $13.0 million from $119.3 million as of March 31, 2025, to $106.3 million as of June 30, 2025.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond control.
• Actual results may differ materially from forward-looking statements due to various factors, including those described in other SEC filings.

Future Outlook

The company plans to commence enrollment in a post-market study for benign thyroid disease treatment in Q3 upon receipt of IRB approvals. It also remains on track to commence FDA IDE pivotal studies for both the cardiac surgical clamp and nsPFA 360 catheter in the next few months, reinforcing the transformational potential of nsPFA energy for treating benign thyroid disease, AF, and additional diseases.

Management Comments

• Paul LaViolette, CEO and Co-Chairman, stated, 'We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs.'
• Paul LaViolette also noted, 'I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360 catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe.'
• Paul LaViolette further commented, 'These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease, AF and additional diseases in the future.'

Industry Context

Pulse Biosciences operates in the innovative bioelectric medicine sector, leveraging its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. This technology aims to non-thermally clear cells while sparing adjacent non-cellular tissue, positioning the company as a potential disruptor in soft tissue ablation (e.g., benign thyroid nodules) and cardiac ablation (e.g., atrial fibrillation). The advancement of clinical trials and FDA submissions indicates progress in bringing novel, potentially less invasive or more effective treatments to market, aligning with broader trends towards precision medicine and advanced medical devices.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were provided in the filing to assess against global benchmarks. The filing mentions 'positive clinical outcomes' and 'improved procedure times' but does not offer quantitative comparisons to established industry standards or competitor devices for thyroid nodule or atrial fibrillation ablation.

Stakeholder Impact

• Shareholders: Mixed impact. Positive clinical advancements could drive long-term value, but increased losses and cash burn present immediate financial concerns.
• Patients: Positive impact due to the advancement of novel nsPFA technology for treating benign thyroid disease and atrial fibrillation, potentially offering new or improved treatment options.
• Employees: The expanding organization to support clinical trials and commercialization suggests potential for continued employment and growth opportunities.

Next Steps

• Commence enrollment in a post-market study for benign thyroid disease treatment in Q3 upon receipt of IRB approvals.
• Commence FDA IDE pivotal studies for the nsPFA Cardiac Surgery System and the nsPFA 360 catheter in the next few months.
• Host a conference call on August 12, 2025, at 1:30 PM PT to discuss business updates and financial results.

Key Dates

Recommendation

While Pulse Biosciences is making significant clinical strides with its nsPFA technology, evidenced by expanded pilot programs, successful patient treatments, and FDA IDE submissions, the financial results for Q2 2025 show a concerning trend of widening losses and increased cash burn. The company's cash position, while currently adequate, is being depleted at an accelerated rate. A seasoned investor would likely 'hold' to monitor the progress of the pivotal clinical trials and the path to commercialization, as the long-term potential of the technology is promising, but the current financial trajectory warrants caution and close observation of future cash management and revenue generation.

Keywords

Pulse Biosciences, nsPFA, Nanosecond Pulsed Field Ablation, soft tissue ablation, thyroid nodule, atrial fibrillation, AF, cardiac surgery, medical device, bioelectric medicine, Q2 2025 earnings